Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02595723 · ClinicalTrials.gov registry record · Phase 4
Phenytoin for Memory Impairment Secondary to Megestrol
A Phase 4 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 21
- Enrollment target
NCT02595723: Completed Phase 4 study, sponsored by University of Texas Southwestern Medical Center.
NCT02595723 is a Phase 4 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 21 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02595723, a Phase 4 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 21 participants
- Enrollment target
Study Summary
This study is designed to test if megestrol acetate induces changes in declarative memory in healthy controls and if pre-administration of phenytoin can ameliorate any induced cognitive impairments.
Primary Outcome
Rey Auditory Verbal Learning Test (RAVLT) is a test of verbal learning and declarative memory. During the test, 15 nouns that are read aloud for 5 consecutive trials. Each trial is followed by a free recall test (participant is asked to recall the words that were just read to them). The sum of correctly recalled words across 5 trials is called the total raw score. The raw scores on the total recall (number of words correct across trials 1-5) are converted to standardized T-scores (Mean=50; SD=10
Interventions
- DRUG Phenytoin 200 mg capsule
- DRUG Megestrol 800 mg liquid
- DRUG Phenytoin-matched Placebo capsule
- DRUG Megestrol-matched liquid Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2015-07 |
| Est. Completion | 2016-12 |
| Phase | Phase 4 |
What the finished NCT02595723 record still lists
NCT02595723 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 4 interventions - of which Phenytoin 200 mg capsule is the first listed.
NCT02595723 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02595723 about?
NCT02595723 is a clinical study titled "Phenytoin for Memory Impairment Secondary to Megestrol". This study is designed to test if megestrol acetate induces changes in declarative memory in healthy controls and if pre-administration of phenytoin can ameliorate any induced cognitive impairments.
What is the current status of trial NCT02595723?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 21 participants. The study started on 2015-07. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02595723?
The interventions under investigation include: Phenytoin 200 mg capsule (DRUG), Megestrol 800 mg liquid (DRUG), Phenytoin-matched Placebo capsule (DRUG), Megestrol-matched liquid Placebo (DRUG).
Who is sponsoring clinical trial NCT02595723?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02595723's enrollment target sits among peer trials
21 1742nd of 2000 higher than 248 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia